4.5 Article

McLean-Harvard International First-Episode Project: Two-Year Stability of ICD-10 Diagnoses in 500 First-Episode Psychotic Disorder Patients

Journal

JOURNAL OF CLINICAL PSYCHIATRY
Volume 72, Issue 2, Pages 183-193

Publisher

PHYSICIANS POSTGRADUATE PRESS
DOI: 10.4088/JCP.09m05311yel

Keywords

-

Funding

  1. National Alliance for Research on Schizophrenia and Depression (NARSAD)
  2. NIH [MH-04844, MH-10948]
  3. Atlas Foundation
  4. Bruce J. Anderson Foundation
  5. McLean Private Donors Research Fund
  6. Spanish Ministry of Education and Science and CIBERSAM
  7. AstraZeneca
  8. Bristol-Myers Squibb
  9. Eli Lilly
  10. Forrest
  11. GlaxoSmithKline
  12. Janssen-Cilag
  13. Jazz
  14. Merck
  15. Novartis
  16. Organon
  17. Otsuka
  18. Pfizer
  19. Sanofi
  20. Servier Corporations
  21. [MH-47370]
  22. [MH-73049]

Ask authors/readers for more resources

Objective: Because clinical and biologic research and optimal clinical practice require stability of diagnoses over time, we determined stability of ICD-10 psychotic disorder diagnoses and sought predictors of diagnostic instability. Method: Patients from the McLean-Harvard International First-Episode Project, conducted from 1989 to 2003, who were hospitalized for first psychotic illnesses (N=500) were diagnosed by ICD-10 criteria at baseline and 24 months, on the basis of extensive prospective assessments, to evaluate the longitudinal stability of specific categorical diagnoses and predictors of diagnostic change. Results: Diagnostic stability averaged 90.4%, ranking as follows: schizoaffective disorder (100.0%) > mania with psychosis (99.0%) > mixed affective episode (94.9%) > schizophrenia (94.6%) > delusional disorder (88.2%) > severe depressive episode with psychotic symptoms (85.2%)> acute psychosis with/without schizophrenia symptoms = unspecified psychosis (all 66.7%) > > acute schizophrenia-like psychosis (28.6%). Diagnoses changed by 24 months of follow-up to schizoaffective disorder (37.5%), bipolar disorder (25.0%), schizophrenia (16.7%), or unspecified non-organic psychosis (8.3%), mainly through emerging affective features. By logistic regression, diagnostic change was associated with Schneiderian first-rank psychotic symptoms at intake > lack of premorbid substance use. Conclusions: We found some psychotic disorder diagnoses to be more stable by ICD-10 than DSM-IV criteria in the same patients, with implications for revisions of both diagnostic systems. J Clin Psychiatry 2011;72(2): 183-193 (C) Copyright 2010 Physicians Postgraduate Press, Inc.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available